Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Remune

Phase 1Small molecule

IImmune Response BioPharma, Inc.

Remune is one of 29 small molecule programs targeting Cachexia. It is currently in Phase 1.

1

Indications

2

Total Trials

0

Active Trials

28

Competitors

Pipeline

Status by Indication[3][1]

Indication

CachexiaActive, not recruiting

CachexiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Cachexia

#DrugCompanyPhaseTrials

Taxotere

Advil

Remicade

OOrganon and Co

Enbrel

ENBREL

Kanglaite

ZZhejiang Kanglaite Pharmaceutical Co.Ltd

Actos

Jakafi

Beyfortus

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cachexia1 trial

Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia

Completed·UUniversity of Rochester·Phase 1·NCT04131426·25 enrolled

Pediatric1 trial

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

Unknown status·IImmune Response BioPharma, Inc.·Phase 2·NCT02291809·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Remune. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remune compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remune. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immune Response BioPharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IImmune Response BioPharma, Inc.

Related News